Pharma’s Biggest Blind Spot: Why 99.9% of Chemical Space Was Never Explored | Dr. Olga Nissan, Ph.D. - Vice President of Business Development, Evogene

Episode notes

Send us Fan Mail Pharma has only explored a tiny fraction - less than one-tenth of one percent - of all possible drug-like molecules. So the question is: what happens when AI suddenly opens up the other 99.9%? Dr. Olga Nissan, Ph.D. is Vice President of Business Development at Evogene ( ) where she leads pharmaceutical partnerships for the company’s ChemPass AI generative chemistry platform - an advanced system designed to dramatically expand the searchable universe of drug-like molecules. With over 15 years of experience spanning biotech, pharma, and computational biology, Dr. Nissan operates at the intersection of science, strategy, and commercialization. Prior to Evogene, she was Co-Founder and CEO of Protica Bio, a precision oncology company focused on translating novel biological insights into therapeutic opportunities. Earlier in her career, she held scientific and operational roles at Teva Pharmaceutical Industries, as well as EcoPhage and BiomX, building expertise across microbiology, molecular biology, and translational R&D. Dr.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• Hiring top-tier talent, the importance of adopting an evolutionary mindset, and taking critical feedback to solve technical problems w/ Sergiy Nesterenko @ QuilterEngineering Founders · on generative AI88 / 100
• What Marketers Can Control When AI Changes Everything with Nick Wedewer, VP of Growth Marketing at Hims & HersThe Partnership Economy · on generative AI87 / 100
• Hiring top-tier talent, leveraging open source models, and staying competitive in the age of AI w/ Benny Chen #267The Engineering Leadership Podcast · on generative AI86 / 100
• Inside Target’s approach to enterprise AI deployment with Sowmya PodilaThe Ecommerce Toolbox: AI in Retail · on generative AI79 / 100
• Navigating AI Risks with Trevor Horwitz from TrustNetB2B Automation Spotlight · on generative AI79 / 100
• SIG Summit Opening Keynote: Kevin Surace on How the Joy Success Cycle Improves the Workplace in an AI RevolutionSourcing Industry Landscape · on generative AI65 / 100

• Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100
• Inside the Global Biotech Ecosystem - Where Innovation Goes Next | Sara Jane Demy - Founder and CEO, Demy-Colton
• Reversing Cellular Age: The Scientist Who Helped Create iPS Cells Reveals What’s Next - Dr. Koji Tanabe, Ph.D. - Founder and CEO, I Peace Inc.
• The End of High Cholesterol? The First Oral PCSK9 Drug Could Change Heart Medicine Forever - Dr. Norman Lepor, MD - Founder and Director, National Heart Institute
• The Hidden Heart Risk: Amgen’s Dr. Paul Burton on the Future of Preventing Heart Attacks - Dr. Paul Burton, M.D., Ph.D., F.A.C.C., M.R.C.S., F.R.C.P. - Senior Vice President and Chief Medical Officer - Amgen